- Home
- ACTG vs LRMR Comparison
ACTG vs LRMR Comparison
Compare ACTG & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTG
- LRMR
- Stock Information
- Founded
- ACTG 1993
- LRMR N/A
- Country
- ACTG United States
- LRMR United States
- Employees
- ACTG N/A
- LRMR N/A
- Industry
- ACTG Multi-Sector Companies
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- ACTG Miscellaneous
- LRMR Health Care
- Exchange
- ACTG Nasdaq
- LRMR Nasdaq
- Market Cap
- ACTG 314.4M
- LRMR 332.1M
- IPO Year
- ACTG 1996
- LRMR N/A
- Fundamental
- Price
- ACTG $3.59
- LRMR $3.45
- Analyst Decision
- ACTG
- LRMR Strong Buy
- Analyst Count
- ACTG 0
- LRMR 7
- Target Price
- ACTG N/A
- LRMR $16.71
- AVG Volume (30 Days)
- ACTG 181.5K
- LRMR 1.8M
- Earning Date
- ACTG 11-05-2025
- LRMR 11-05-2025
- Dividend Yield
- ACTG N/A
- LRMR N/A
- EPS Growth
- ACTG N/A
- LRMR N/A
- EPS
- ACTG 0.05
- LRMR N/A
- Revenue
- ACTG $283,949,000.00
- LRMR N/A
- Revenue This Year
- ACTG $109.86
- LRMR N/A
- Revenue Next Year
- ACTG N/A
- LRMR N/A
- P/E Ratio
- ACTG $71.73
- LRMR N/A
- Revenue Growth
- ACTG 71.28
- LRMR N/A
- 52 Week Low
- ACTG $2.70
- LRMR $1.61
- 52 Week High
- ACTG $4.79
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- ACTG 56.87
- LRMR 39.35
- Support Level
- ACTG $3.24
- LRMR $3.16
- Resistance Level
- ACTG $3.50
- LRMR $4.50
- Average True Range (ATR)
- ACTG 0.14
- LRMR 0.30
- MACD
- ACTG 0.00
- LRMR -0.10
- Stochastic Oscillator
- ACTG 72.92
- LRMR 24.09
About ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.